Cancer Genetics (CGIX) Shares Up 10%
Shares of Cancer Genetics Inc (NASDAQ:CGIX) shot up 10% during mid-day trading on Wednesday . The company traded as high as $0.36 and last traded at $0.33. 553,427 shares were traded during mid-day trading, an increase of 77% from the average session volume of 312,127 shares. The stock had previously closed at $0.30.
A number of research firms have issued reports on CGIX. HC Wainwright set a $3.00 target price on Cancer Genetics and gave the stock a “buy” rating in a research report on Wednesday, August 15th. Maxim Group reissued a “hold” rating on shares of Cancer Genetics in a research report on Tuesday, August 14th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $4.50.
The stock has a market capitalization of $12.53 million, a PE ratio of -0.42 and a beta of 1.10. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.66 and a quick ratio of 0.66.
Cancer Genetics Company Profile (NASDAQ:CGIX)
Cancer Genetics, Inc engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomaker solutions, biorepository solutions, consulting, cytogenetics testing, nucleic acid extraction and purification, flow cytometry, Focus::NGS Panel, gene expression analyses, genotyping, and pharmacogenomics.
Featured Story: What is a Candlestick Chart?
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.